Progyny (NASDAQ:PGNY) Stock Price Expected to Rise, Truist Financial Analyst Says

Posted by Francis Steltz on May 11th, 2026

Progyny (NASDAQ:PGNY – Get Free Report) had its target price lifted by stock analysts at Truist Financial from $28.00 to $30.00 in a research note issued to investors on Monday,Benzinga reports. The firm currently has a “buy” rating on the stock. Truist Financial’s target price would suggest a potential upside of 32.33% from the stock’s previous close.

Other analysts have also recently issued reports about the company. Citizens Jmp boosted their price objective on Progyny from $30.00 to $31.00 and gave the company a “market outperform” rating in a research report on Monday. JPMorgan Chase & Co. set a $35.00 price objective on Progyny in a research report on Wednesday, January 21st. Jefferies Financial Group reiterated a “buy” rating and issued a $30.00 price target on shares of Progyny in a research report on Friday, March 6th. Barclays decreased their target price on Progyny from $29.00 to $23.00 and set an “overweight” rating on the stock in a report on Friday, March 20th. Finally, Canaccord Genuity Group decreased their target price on Progyny from $26.00 to $19.00 and set a “hold” rating on the stock in a report on Wednesday, March 11th. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $28.18.

View Our Latest Analysis on PGNY

Progyny Stock Down 4.4%

Shares of PGNY stock traded down $1.05 during trading hours on Monday, reaching $22.67. 702,807 shares of the company’s stock were exchanged, compared to its average volume of 1,521,556. Progyny has a fifty-two week low of $16.10 and a fifty-two week high of $28.75. The stock has a market capitalization of $1.78 billion, a P/E ratio of 29.50, a P/E/G ratio of 1.37 and a beta of 0.91. The business has a fifty day moving average price of $17.87 and a 200-day moving average price of $21.69.

Progyny (NASDAQ:PGNY – Get Free Report) last released its quarterly earnings data on Thursday, May 7th. The company reported $0.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.26 by $0.03. The business had revenue of $328.50 million for the quarter, compared to analysts’ expectations of $326.47 million. Progyny had a return on equity of 13.34% and a net margin of 5.23%.Progyny’s quarterly revenue was down 26.4% on a year-over-year basis. During the same period in the previous year, the business posted $0.17 earnings per share. Progyny has set its FY 2026 guidance at 1.980-2.09 EPS and its Q2 2026 guidance at 0.500-0.53 EPS. As a group, research analysts expect that Progyny will post 1.12 EPS for the current fiscal year.

Insider Activity

In other Progyny news, EVP Allison Swartz sold 4,657 shares of the stock in a transaction dated Tuesday, March 3rd. The stock was sold at an average price of $17.40, for a total value of $81,031.80. Following the completion of the sale, the executive vice president directly owned 89,879 shares in the company, valued at $1,563,894.60. This represents a 4.93% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold 7,455 shares of company stock valued at $129,515 in the last ninety days. 9.90% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Progyny

Several large investors have recently modified their holdings of PGNY. Wellington Management Group LLP increased its holdings in shares of Progyny by 260.9% in the fourth quarter. Wellington Management Group LLP now owns 2,243,268 shares of the company’s stock worth $57,607,000 after acquiring an additional 1,621,688 shares in the last quarter. Fort Washington Investment Advisors Inc. OH increased its holdings in shares of Progyny by 46.9% in the first quarter. Fort Washington Investment Advisors Inc. OH now owns 2,693,393 shares of the company’s stock worth $45,734,000 after acquiring an additional 859,289 shares in the last quarter. Loomis Sayles & Co. L P bought a new stake in shares of Progyny in the fourth quarter worth about $19,917,000. Barclays PLC increased its holdings in shares of Progyny by 79.2% in the third quarter. Barclays PLC now owns 1,575,470 shares of the company’s stock worth $33,904,000 after acquiring an additional 696,447 shares in the last quarter. Finally, Ameriprise Financial Inc. grew its holdings in shares of Progyny by 37.6% during the second quarter. Ameriprise Financial Inc. now owns 1,996,957 shares of the company’s stock worth $43,933,000 after buying an additional 545,431 shares in the last quarter. 94.93% of the stock is currently owned by institutional investors.

Progyny Company Profile

(Get Free Report)

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.